RB1

protein-coding

RB transcriptional corepressor 1, the group of Receptor ligands

Gene summary

The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. [provided by RefSeq, Jul 2008]

Previous symbols:
  • OSRC

MANE transcript

NM_000321.3

Inheritance

AD

ClinVar variants

P:916U:1622B:931

Top phenotype

Retinoblastoma

gnomAD constraint

pLI —, LoF o/e 0.05

Max pathogenic AF

—

Genomic locus

chr13:48,303,744-48,599,436

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~295.7 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

hereditary retinoblastomaSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0018160

Submitter: Labcorp Genetics (formerly Invitae)

melanomaMODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0005105

Submitter: Ambry Genetics

hereditary retinoblastomaSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018160

Submitter: Orphanet

hereditary retinoblastomaDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018160

Submitter: Ambry Genetics

hereditary retinoblastomaDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018160

Submitter: G2P

retinoblastomaDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0008380

Submitter: ClinGen

Retinoblastoma (RB) is an embryonic malignant neoplasm of retinal origin. It almost always presents in early childhood and is often bilateral. The retinoblastoma gene (RB1) was the first tumor suppressor gene identified based on location in the region of 13q14 germline deletion in some patients with retinoblastoma (PMID: 3480530). Oncogenic point mutations in RB1 were first reported by Yandell DW, et al., 1989 (PMID: 2594029). RB1 encodes a negative regulator of the cell cycle through its ability to bind the transcription factor E2F and repress transcription of genes required for S phase (PMID: 10647931). There is abundant evidence published associating the RB1 gene with retinoblastoma. Multiple case level studies (PMID: 2594029, 25928201) and a case control study (PMID: 28193182) have been performed with retinoblastoma patients that have variants in the RB1 gene. The variants include single amino acid changes, the whole gene deletion (about 3-5%) and nonsense or frameshift LOF variants. Many de novo variants were reported. A significant amount of case-level data is available, but the maximum points for genetic evidence has been reached (12 points). A zebrafish model of RB1 has been established to show development of retinoblastoma consistent with the disease phenotype. Tumor formation was observed when the IRBP-Cre:Rb1-/- mice were crossed with Tp53 mice to heterozygosity. In summary, RB1 is definitively associated with autosomal dominant retinoblastoma. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.

Clinical Genomic Database (CGD)

RetinoblastomaAD

Manifestation: Oncologic

Intervention: Oncologic

Rationale: Frequent and regular eye examination (including under anesthesia if necessary) starting in infancy is indicated in order to detect ocular neoplasms, which may allow early detection and treatment; Awareness of the risk of additional neoplasms may allow early detection and treatment based on signs/symptoms (eg, bone pain); Limiting exposure to DNA-damaging agents (including high-dose radiotherapy) may be beneficial

Refs: 1066869; 268552; 6930517; 6654325; 6696673; 2876425; 2885916; 2895471; 3175621; 7795591; 8651278; 9311732; 10502774; 10561222; 11097606; 11449317; 11709011; 11382640; 11382638; 12096963; 12523888; 12541220; 12488270; 12598449; 14996857; 16936756; 16631255; 16606893; 17613328; 17096365; 19280657; 20301625; 21150892; 22084214; 22103627; 22237022; 22293180; 22355046Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to RB1 variants in ClinVar

28 Conditions Cataloged
RetinoblastomaTotal: 3353
Hereditary cancer-predisposing syndromeTotal: 2280
not providedTotal: 414
Malignant tumor of urinary bladderTotal: 134
not specifiedTotal: 133
Hereditary retinoblastomaTotal: 95
RB1-related disorderTotal: 78
Inborn genetic diseasesTotal: 43

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_000321.3. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
4
clinvar
3
clinvar
15
clinvar
672
clinvar
17
clinvar
711
missense
15
clinvar
36
clinvar
1561
clinvar
235
clinvar
6
clinvar
1853
nonsense
175
clinvar
10
clinvar
3
clinvar
188
start loss
1
clinvar
2
clinvar
3
frameshift
439
clinvar
41
clinvar
19
clinvar
499
splice donor/acceptor (+/-2bp)
148
clinvar
44
clinvar
22
clinvar
1
clinvar
215
Total7811351622908233469

Highest pathogenic variant AF is 0.004362775

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 31 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_000321.3RefSeqNP_000312.227MANE Select
ENST00000267163.6EnsemblENSP00000267163.427MANE Select
NM_001407165.1RefSeqNP_001394094.127Standard
NM_001407166.1RefSeqNP_001394095.117Standard

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
rb1Danio rerio

Structure: retinal ganglion cell

Quality: misrouted

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Non-small cell lung cancer - Homo sapiens (human)
  • Chronic myeloid leukemia - Homo sapiens (human)
  • Gastric cancer - Homo sapiens (human)
  • Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human)
  • Melanoma - Homo sapiens (human)

Biological Process

  • G1/S transition of mitotic cell cycle
  • negative regulation of transcription by RNA polymerase II
  • regulation of cell growth
  • tissue homeostasis
  • aortic valve morphogenesis

Molecular Function

  • proximal promoter sequence-specific DNA binding
  • RNA polymerase II regulatory region DNA binding
  • RNA polymerase II activating transcription factor binding
  • DNA binding
  • DNA-binding transcription factor activity

Cellular Component

  • chromatin
  • nucleus
  • nucleoplasm
  • transcription factor complex
  • spindle

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000267163
Coding exons
27
Length
178236
Individuals with no LoFs
125681
Homozygous LoFs
0
Heterozygous LoFs
5
Defined
125686
p
0.0000199
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense2.673114750.6550.00002386073
Missense (PolyPhen)86186.590.46092409
Synonymous0.4881521600.9510.000007821707
Loss of Function6.93361.80.04860.00000378715

Population LoF Frequency

PopulationCAFp-valueStatus
African0.0000680.000062rare
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian00.0absent
Finnish00.0absent
European (Non-Finnish)0.0000370.000035rare
South Asian00.0absent
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity. {ECO:0000250, ECO:0000269|PubMed:15084261}.;
Disease
DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]: Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated. {ECO:0000269|PubMed:10671068, ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883, ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558, ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327, ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116, ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452, ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating in bone-forming cells, affecting the ends of long bones. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.970

Intolerance Scores

LoFtool
0.00806
RVIS EVS
-0.69
RVIS percentile EVS
15.12

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
1.00

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.